|
Stabilization of a progressive hemangioblastoma under
treatment with thalidomide
Maria Piribauer,
Thomas Czech, Karin Dieckmann, Peter Birner,
Johannes A. Hainfellner, Daniela
Prayer, Barbara Fazeny-Dörner, Georg Weinländer
and
Christine Marosi
Clinical Division of Oncology, Department of Medicine I
(M.P.,B.F.-D,G.W.,C.M.), Department
of Neurosurgery (T.C.), Department for Radiooncology (K.D.), Department
of Pathology (P.B.), Department of Neuropathology (J.A.H.), Department
of Neuroradiology (D.P.), University Hospital Vienna, Währinger Gürtel, Vienna, Austria.
After the second recurrence of spinal seeding in
hemangioblastoma not associated to von-Hippel–Lindau disease, we treated an
adult female patient with thalidomide 200 mg orally/day at night for longer than
1 year.
The patient reported subjective relief of symptoms after 1 month.
Magnetic resonance imaging (MRI) controls 1, 6 and 11 months after begin of
thalidomide treatment did not show further tumor progression.
She remained
wheelchair-bound, but mobility of her arms continuously improved.
There was no
thalidomide associated side-effect in this patient until her death from
pneumonia due to legionnaire’s disease.
Antiangiogenic
treatment with interferon (IFN) α-2a and IFN α-2b
and with SU 5416 has been reported to be effective and well tolerated in several
patients with previously progressive angioblastomas and hemangioblastomas.
This case adds further evidence of the efficacy of an
antiangiogenic treatment concept in a progressive hemangioblastoma.
© 2004
Kluwer Academic Publishers.
Source: doi:10.1023/B:NEON.0000014493.88402.dc
|
